Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Leerink Partners Remains Bullish on Biogen (BIIB) Following 3Q Earnings Results
October 21, 2015 1:42 PM EDTLeerink Partners reiterated an Outperform rating and $425.00 price target on Biogen (NASDAQ: BIIB) following the company's 3Q15 earnings results. BIIB reported a 3Q beat on all top and bottom line levels. 3Q sales of 2.78 bn. vs. consensus estimates of $2.6B, 3Q non-GAAP EPS of 4.48 vs.... More
Cowen Remains Bullish as Biogen (BIIB) Reports 3Q EPS Beat
October 21, 2015 1:36 PM EDTCowen reiterated an Outperform rating and $368.00 price target on Biogen (NASDAQ: BIIB) following the company's 3Q15 earnings results. BIIB reported strong Q3 non-GAAP EPS of $4.48 vs. consensus of $3.84E, on revenue of $2.8B.
Analyst Eric Schmidt commented, "BIIB reported Q3 revenue and earnings well above... More
Biogen's (BIIB) Phase 3 ASCEND Trial Missed Primary, Secondary Endpoints
October 21, 2015 7:32 AM EDTThe Phase 3 ASCEND study investigating natalizumab in the treatment of secondary progressive multiple sclerosis (SPMS) did not achieve its primary and secondary endpoints, Biogen (NASDAQ: BIIB) reported today. During the study, natalizumab was generally well tolerated and adverse events were consistent with its known safety profile.
ASCEND evaluated the efficacy and... More
Biogen (BIIB) Tops Q3 EPS by 68c; Announces Corp. Restructuring; Boosts FY15 EPS Outlook
October 21, 2015 7:31 AM EDTBiogen (NASDAQ: BIIB) reported Q3 EPS of $4.48, $0.68 better than the analyst estimate of $3.80. Revenue for the quarter came in at $2.39 billion versus the consensus estimate of $2.65 billion.
Corporate Restructuring
The Company plans to substantially complete the majority of the 11% reduction of its global workforce by the end of 2015. The Company is in the process of notifying employees affected by the restructuring, and... More
